AbbVie Stock (NYSE:ABBV)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$195.45

52W Range

$135.85 - $199.95

50D Avg

$192.89

200D Avg

$174.34

Market Cap

$343.18B

Avg Vol (3M)

$4.71M

Beta

0.62

Div Yield

$6.20 (3.16%)

ABBV Company Profile


AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Show More

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

50,000

IPO Date

Jan 02, 2013

Website

ABBV Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Other Neuroscience$276.00M$475.00M-
Duodopa$468.00M$458.00M-
Botox Therapeutic$2.99B$2.72B-
Ubrelvy$815.00M--
Vraylar$2.76B$2.04B-
Linzess/Constella$1.11B$1.03B-
MAVYRET$1.43B$1.54B-
Other Products$3.04B$4.14B$2.67B
SKYRIZI$7.76B$5.17B-
RINVOQ$3.97B$2.52B-
H U M I R A$14.40B$21.24B-
VENCLEXTA$2.29B$2.01B-
Imbruvica$3.60B$4.57B-
Restasis$436.00M$666.00M-
Ozurdex$472.00M--
Other Eye Care$803.00M$1.18B-
Lumigan/Ganfort$432.00M$514.00M-
Alphagan/Combigan$272.00M$346.00M-
Other Aesthetics$1.23B$1.29B-
Juvederm Collection$1.38B$1.43B-
Botox Cosmetic$2.68B$2.62B-
Qulipta$408.00M--

Fiscal year ends in Dec 23 | Currency in USD

ABBV Financial Summary


Dec 23Dec 22Dec 21
Revenue$54.32B$58.05B$56.20B
Operating Income$17.43B$18.12B$17.92B
Net Income$4.86B$11.84B$11.54B
EBITDA$18.10B$26.58B$26.45B
Basic EPS$2.75$6.65$6.48
Diluted EPS$2.74$6.63$6.45

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Jul 25, 24 | 1:04 PM
Q1 24Apr 26, 24 | 1:25 PM
Q4 23Feb 02, 24 | 1:00 PM

Peer Comparison


TickerCompany
LLYEli Lilly and Company
MRKMerck & Co., Inc.
AMGNAmgen Inc.
JNJJohnson & Johnson
BMYBristol-Myers Squibb Company
GILDGilead Sciences, Inc.
PFEPfizer Inc.